XML 51 R31.htm IDEA: XBRL DOCUMENT v3.25.2
SHARE-BASED COMPENSATION AND WARRANTS (Tables)
12 Months Ended
Jun. 30, 2025
SHARE-BASED COMPENSATION AND WARRANTS  
Schedule of the number of shares authorized, outstanding, and available for future grants under stock option

Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Company’s equity incentive plans as of June 30, 2025:

    

Number of Shares

Description

    

Authorized

    

Outstanding

    

Available

2015 Plan

 

15,500

15,500

 

2016 Plan

 

122,900

 

122,900

 

2019 Plan

 

200,000

 

200,000

 

2021 Plan

13,879,670

13,321,094

558,576

Inducement Awards

1,500,000

425,000

1,075,000

Total

 

15,718,070

 

14,084,494

 

1,633,576

Schedule of the stock option plans

The following table sets forth a summary of the combined stock option activity under the Company’s equity incentive plans and inducement awards, for the fiscal years ended June 30, 2025 and 2024:

2025

2024

    

Shares

    

Price (1)

    

Term (2)

Shares

    

Price (1)

    

Term (2)

Outstanding, beginning of fiscal year

 

10,890,540

$

3.82

8.1

8,745,400

$

4.56

 

8.8

Granted

3,246,300

4.57

2,641,500

1.31

Exercised

(488,742)

(3)

2.85

(81,588)

(3)

3.02

Expired

(69,666)

12.17

(111,059)

6.11

Forfeited

(550,438)

3.08

(303,713)

2.63

Outstanding, end of fiscal year

 

13,027,994

(4)

 

4.03

 

7.7

10,890,540

(4)

 

3.82

 

8.1

Vested, end of fiscal year

 

7,127,835

(5)

 

4.48

 

6.9

4,891,745

(5)

 

5.39

 

7.7

(1)Represents the weighted average exercise price.
(2)Represents the weighted average remaining contractual term until the stock options expire.
(3)The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the year ended June 30, 2025 and 2024, was $0.9 million and $0.1 million, respectively.
(4)As of June 30, 2025 and 2024, the intrinsic value of outstanding stock options was approximately $14.9 million and $14.6 million, respectively.
(5)As of June 30, 2025 and 2024, the aggregate intrinsic value of vested stock options was approximately $8.5 million and $4.1 million, respectively.
Schedule of the fair value of stock options

The fair value of stock options was estimated on the dates of grant using the BSM option-pricing model, with the following weighted-average assumptions for the fiscal years ended June 30, 2025 and 2024:

    

2025

2024

Market price of common stock on grant date

$

4.57

$

1.31

Expected volatility

    

84

%

99

%

Risk free interest rate

 

4.2

%

4.2

%

Expected term (years)

 

5.9

5.6

Dividend yield

 

0

%

0

%

Schedule of the combined RSU activity

The following table sets forth a summary of the RSU activity under the Company’s 2021 Plan, for the fiscal years ended June 30, 2025 and 2024:

2025

2024

    

Shares

    

Price (1)

Shares

    

Price (1)

Unvested, beginning of fiscal year

 

$

$

Granted

1,056,500

4.55

Vested

Forfeited

Unvested, end of fiscal year

 

1,056,500

 

4.55

 

(1)Represents the weighted average grant price based on the closing market price of each of the RSU grants.
Schedule of share-based compensation expense

Share-based compensation expense is included under the following captions in the consolidated statements of operations for the fiscal years ended June 30, 2025 and 2024 (in thousands):

2025

    

2024

Research and development

$

3,502

$

3,379

General and administrative

 

3,619

 

3,981

Total

$

7,121

$

7,360

Legacy warrants  
SHARE-BASED COMPENSATION AND WARRANTS  
Schedule of warrant activity The following table sets forth a summary of activity related to the Legacy Warrants for the fiscal years ended June 30, 2025 and 2024:

2025

2024

    

Shares

    

Price (1)

    

Term (2)

    

Shares

    

Price (1)

    

Term (2)

Outstanding, beginning of fiscal year

 

860,562

  

$

20.28

 

3.2

 

888,238

  

$

22.10

 

4.1

Expirations

 

(10,120)

  

52.20

 

  

 

(27,676)

  

 

78.60

 

  

Outstanding, end of fiscal year

 

850,442

  

 

19.90

 

2.3

 

860,562

  

 

20.28

 

3.2

(1)Represents the weighted average exercise price.
(2)Represents the weighted average remaining contractual term for the number of years until the warrants expire.